Test Price
2,800 AED✅ Home Collection Available
ILDR1 Gene Deafness Autosomal Recessive Type 42 Genetic Test (NGS) in UAE | 2,800 AED | DNA Labs UAE
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 15189:2022 Accredited NGS Processing.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily from 8 AM to 11 PM).
- Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation by DHA-licensed Consultant Medical Genetics.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The ILDR1 Gene Deafness, Autosomal Recessive Type 42 Genetic Test uses Next‑Generation Sequencing (NGS) to identify pathogenic variants in the ILDR1 gene associated with non-syndromic sensorineural hearing loss (DFNB42). This assay provides comprehensive coverage of all coding exons and splice‑site regions, enabling precise carrier screening, diagnostic confirmation, and pre‑marital risk assessment. It is a cornerstone for personalized audiological management and genetic counseling in the UAE.
| Feature | Our Test (NGS Panel) | Standard PCR‑Based Genotyping |
|---|---|---|
| Diagnostic Precision | >99.9% sensitivity; covers entire ILDR1 coding region + splice sites | Targeted known variants only; may miss private mutations |
| Methodology | NGS (Illumina® platform) with bioinformatic validation | Sanger sequencing or PCR‑RFLP, limited to few hotspots |
| Turnaround Time | 3–4 weeks | 4–8 weeks (often sent abroad) |
| Carrier & Prenatal Capability | Yes – comprehensive variant identification for family planning | Limited; requires prior knowledge of familial mutation |
Physician Insight & Safety Protocols
"As a Consultant in Medical Genetics, I emphasize that while this genetic test provides crucial information for non-syndromic hearing loss, it must be interpreted within the context of a full clinical and audiological evaluation. It is not a substitute for professional medical advice. Please continue all prescribed treatments and consult your geneticist before making any decisions."
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Important Medication Advisory
Do not discontinue or alter any prescribed medications without consulting your physician. This genetic test does not replace clinical follow-up.
Patient Exclusion Criteria
- Individuals with severe coagulopathy or active infection at the venipuncture site should postpone the blood draw.
- For minors (below 18 years), a legal guardian must provide informed consent as per UAE Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL).
- Emergency Warning: This genetic test is not for acute hearing loss emergencies. If sudden hearing loss or vertigo occurs, seek immediate ENT evaluation at an emergency department.
- Inability to understand the informed consent process (requires a legally authorised representative).
Patient FAQ & Clinical Guidance
1. What is the purpose of this genetic test?
This test sequences the entire ILDR1 gene to detect mutations responsible for autosomal recessive non-syndromic hearing loss type 42, aiding in accurate diagnosis, carrier screening, and family planning. It is performed using advanced NGS technology with high sensitivity.
2. What sample types are accepted and how is home collection arranged?
We accept whole blood, extracted DNA, or one drop of blood on an FTA card. Our DHA-licensed phlebotomists provide VIP mobile phlebotomy and temperature-controlled cold-chain home collection across Dubai, Abu Dhabi, and Sharjah, available daily from 8 AM to 11 PM.
3. How are results interpreted and what follow-up is recommended?
Results are reported as positive, negative, or variant of uncertain significance (VUS). A complimentary post-test teleconsultation with our Consultant Medical Genetics will explain the findings and recommend next steps, including audiometry and familial screening.
UAE Regulatory & Data Privacy Adherence
This service fully complies with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical testing safety and patient consent are governed under Federal Decree-Law No. 4 of 2016 on Medical Liability. All genetic counselling is conducted by DHA-licensed professionals. Laboratory operations are accredited under ISO 15189:2022 and ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139). DHA Facility License No. 1143.
Clinical & Logistical Metadata
| Test Name | ILDR1 Gene Deafness Autosomal Recessive Type 42 Genetic Test (NGS) |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 weeks |
| Sample Type / Matrix | Whole blood, extracted DNA, or FTA card (peripheral blood sample) |
| Methodology Used | Next-Generation Sequencing (NGS) – Illumina® platform |
| ICD-10-CM Code | H90.3, Z13.79 |
| LOINC Code | 87409-1 |
| DHA Facility License & Laboratory Address | DHA License No: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians